Generics
Indivior reaches settlement in patent infringement case with Dr. Reddy's Laboratories
24 June 2022 -

Indivior plc (LON:INDV), a pharmaceutical company that develops medicines to treat substance use disorders and serious mental illnesses, announced on Friday that together with Aquestive Therapeutics Inc (NASDAQ:AQST) it has entered into a settlement agreement with Dr. Reddy's Laboratories Ltd (DRL) (NSE:DRREDDY) and its subsidiaries.

Indivior said that this settlement will resolve patent litigation relating to DRL's generic buprenorphine and naloxone sublingual film, a therapeutic equivalent generic version of SUBOXONE (buprenorphine and naloxone) sublingual film.

The confidential settlement resolves all claims between the parties and the amount paid by Indivior to DRL pursuant to the settlement is consistent with its previously disclosed reserve amount.

Login
Username:

Password:


Related Headlines